Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Study of VIC-1911 Combined With Osimertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGRF- Mutation

NCT05489731 is registered in ClinicalTrials.gov with Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT05489731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05489731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Study of VIC-1911 Combined With Osimertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGRF- Mutation
Lead sponsor
Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
September 21, 2022
Completion date
April 24, 2024
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer